Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

WAGO pathway

ABSTRACT: WAGO pathway

OTHER RELATED OMICS DATASETS IN: GSE18231

PROVIDER: PRJNA119615 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR030710.fastq.gz	Fastqsanger.gz
	SRR030711.fastq.gz	Fastqsanger.gz
	SRR030712.fastq.gz	Fastqsanger.gz
	SRR030713.fastq.gz	Fastqsanger.gz
	SRR030714.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 10

Similar Datasets

AGO pathway

Project description:AGO pathway

| PRJNA121635 | ENA

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

Project description:This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating patients with advanced or metastatic sarcoma. Vismodegib may slow the growth of tumor cells. Gamma-secretase/notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vismodegib together with gamma-secretase/notch signalling pathway inhibitor RO4929097 may be an effective treatment for sarcoma.

| 2091475 | ecrin-mdr-crc

Notch signaling pathway

Project description:A model of Notch pathway which is reproduced from the Wang et al. paper (2013).

| 1cd | Physiome Model Repository

Crosslinking/mass spectrometry analysis of Fanconi anemia (FA) pathway FANCD2-FANCI complexes

Project description:DNA interstrand crosslinks (ICLs) are repaired by the Fanconi anemia (FA) pathway. The FA pathway is activated by phosphorylation of FANCI in FANCD2-FANCI complex. To investigate how phosphorylation regulates FA pathway activation and function, recombinant FANCD2-FANCI complexes prepared using either the wild-type FANCI or the phosphomimetic FANCI, were comparied using crosslinking/mass spectrometry.

2022-11-18 | PXD031632 | JPOST Repository

Targeting Hedgehog pathway by Smoothened Antagonist

Project description:Targeting Hedgehog pathway by Smoothened Antagonist

| PRJNA720577 | ENA

Dhurrin Pathway in Sugarcane

Project description:Identification and expression characterization of dhurrin pathway genes in sugarcane

| PRJEB37265 | ENA

The hippo pathway effector protein YAP modulated resistance to trametinib neuroblastomas with hyperactivated RAS pathway signalling

Project description:The hippo pathway effector protein YAP modulated resistance to trametinib neuroblastomas with hyperactivated RAS pathway signalling

| PRJNA540060 | ENA

A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors

Project description:This is a Phase 1/2, multicenter, open label, first in human (FIH) study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.

| 2377928 | ecrin-mdr-crc

Study of WNT974 in combination with LGX818 and cetuximab in patients with BRAF-mutant metastatic colorectal cancer (mCRC) and Wnt pathway mutations

Project description:Primary objectives: Phase Ib: To estimate the MTD(s) and/or RP2D(s) of the triple combination of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant CRC harboring upstream Wnt pathway mutations. Phase II: To estimate the preliminary anti-tumor activity of the RP2D(s) of WNT974 in combination with LGX818 and cetuximab in patients with BRAFV600-mutant CRC harboring upstream Wnt pathway mutations Note: Further enrollment to the study has been discontinued as of 21 March 2016. Therefore, references to phase II study design and objectives are no longer relevant. Primary endpoints: 1. Phase Ib: To estimate the MTD(s)/RP2D(s) of the triple combination of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant, KRAS wild-type (WT) mCRC harboring upstream Wnt pathway mutations, as measured by incidence of dose-limiting toxicities (DLTs) and exposure to WNT974 and LGX818 as measured by PK parameters. 2. Phase II: To estimate the preliminary anti-tumor activity at the RP2D(s) of the combination of WNT974, LGX818 and cetuximab, in patients with BRAFV600-mutant metastatic colorectal cancer harboring upstream Wnt pathway mutations, based on the Overall Response Rate (ORR). Note: Further enrollment to the study has been discontinued as of 21 March 2016. Therefore, references to phase II study design and objectives are no longer relevant.

| 2533488 | ecrin-mdr-crc

Viral factors inhibit TOR pathway

Project description:Novel factors of viral origin inhibit TOR pathway gene expression

| PRJEB29401 | ENA